• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

New Supplement Addresses Muscle Atrophy in Dogs

June 12, 2018
Amanda Carrozza

With the launch of its first nutritional supplement for dogs, a New Jersey biotherapeutics and bionutrition company has entered the veterinary health care marketplace.

Watching patients suffer from any form of degenerative myelopathy or muscle loss is heartbreaking, regardless of its commonality. While researchers continue to work toward finding therapies that halt disease progression and improve quality of life, a new dietary supplement has entered the market to support canine muscle health.

Earlier this month, Myos Rens Technology Inc. announced the launch of its first veterinary health supplement: MYOS Canine Muscle Formula. Historically, the company has focused its research and products on improving muscle health in humans and is best known for its proprietary formula, Fortetropin. The product is a bioactive composition derived from fertilized egg yolk that helps build lean muscle, and it serves as the active ingredient in the new supplement.

“We view the veterinary supplement market as an untapped growth opportunity for the company,” Joseph Mannello, CEO of Myos Rens Technology, said. “To the best of our knowledge, there is no pet health supplement product that addresses muscle atrophy.”

RELATED:

  • The Importance of Vitamin D in Canine Health
Advertisement
  • Gene Therapy Improves Muscular Dystrophy in Dogs

The company has conducted a number of human clinical trials to test the efficacy of Fortetropin and has found it to be the only safe, natural myostatin-reducing agent available with a clinically demonstrated positive effect on both muscle thickness and lean body mass when compared with placebo.

“Over the last year, Fortetropin consumers reached out to tell us about their personal experiences using our products and their observations of their dogs who consumed Fortetropin, Mannello explained. “We then took it a step further and tested Fortetropin products with veterinarians, who reported that older dogs engaged in more physical activity after consuming Fortetropin and resumed certain activities that were thought to have stopped because of age.”

That initial feedback from veterinarians and pet owners led Myos Rens Technology to undertake a clinical study at Kansas State University to determine whether daily supplementation with Fortetropin is effective in reducing muscle atrophy in dogs that undergo a tibial plateau leveling osteotomy. According to Mannello, the results will be announced by the end of the year.

With the launch of MYOS Canine Muscle Formula, Myos Rens Technology joins the $580 million veterinary supplements market. The company plans to distribute the product through established veterinary practices throughout the country, offering customers a home delivery autoship option. The supplement is available for dogs of all sizes and comes as a powder that can be mixed into a dog’s regular meals. A single canister provides approximately 60 servings, which equates to a 2-month supply of product for a medium-sized dog.

“The feedback we have received from veterinarians and pet owners has been overwhelmingly positive. Given that lean muscle mass is inversely associated with mortality from all causes in humans, we believe veterinarians, as well as consumers, will appreciate the muscle-enhancing benefits of adding Fortetropin to their dog's diet,” Mannello said.


Advertisement

Latest News

Free microchipping event to take place in Chicago

Zoo announces birth of critically endangered red wolf pups

Study reveals most pet parents wouldn't leave home to escape disaster if they couldn't bring pets

New ASAP Vet urgent care opens in Austin, Texas

View More Latest News
Advertisement